Three-dimensional (3D) in vitro models in the drug development pipeline can help selecting the most promising and safe drug candidates prior to clinical trials, reducing and sometimes even replacing animal studies in accordance with the “3Rs (Reduction, Refinement and Replacement) principle”. Furthermore, the development of 3D organoids from cells harvested from patients has opened new avenues towards a personalized medicine approach.
Moreover, the development and translational investigation of new therapies or treatments for degenerative or regenerative applications can be expedited by the latest precision medicine and artificial intelligence approaches. This facilitates drug formulation and screening with a direct input into the regulatory science and industrial technological innovation pipeline. Consideration for Chemical, Food and Medical safety are also to not be excluded as read-across knowledge.
This Research Topic covers the areas of the development, validation and use of in vitro 3D models where novel methodologies and findings demonstrate the key role of three-dimensionality in biology and provide a platform to increase the success rate in translating new degenerative or regenerative solutions (e.g., diagnostics, treatment, follow up) into real clinical innovative approaches to the benefit of patients. Original interdisciplinary research, pre-clinical methods validation and clinical investigations should be all considered as part of the shared open access knowledge which we are aiming to achieve with this Research Topic.
The overall scope of this Research Topic is to create a transparent forum of open access materials focused on the state of the art on 3D biology to date.
We encourage submissions addressing themes such as:
• Novel in vitro 3D models and organ-/lab-on-a-chip
• New methods/methodologies with application in 3D biology
• Drug testing using complex 3D in vitro cultures and/or in silico models
• Regulatory Science focused on 3D model validation
• Case studies focused on translational aspects for drug development
• Case studies focused on read-across methodologies
• Novel protocols and techniques for imaging and screening
• Screening of new materials for biomedical applications
• Regenerative and degenerative applications
• Predictive modelling for safety and personalized medicine
• Interdisciplinary original research in 3D biology
Original topical mini-review articles or perspectives focused on the current state of knowledge regarding the above mentioned themes are also welcome.
-----------------------------------------------------------------
Dr. Davide Staedler is CEO of TIBIO Sagl, a consulting company, and chief scientific officer of Scitec Research S.A., a private analytical laboratory. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Three-dimensional (3D) in vitro models in the drug development pipeline can help selecting the most promising and safe drug candidates prior to clinical trials, reducing and sometimes even replacing animal studies in accordance with the “3Rs (Reduction, Refinement and Replacement) principle”. Furthermore, the development of 3D organoids from cells harvested from patients has opened new avenues towards a personalized medicine approach.
Moreover, the development and translational investigation of new therapies or treatments for degenerative or regenerative applications can be expedited by the latest precision medicine and artificial intelligence approaches. This facilitates drug formulation and screening with a direct input into the regulatory science and industrial technological innovation pipeline. Consideration for Chemical, Food and Medical safety are also to not be excluded as read-across knowledge.
This Research Topic covers the areas of the development, validation and use of in vitro 3D models where novel methodologies and findings demonstrate the key role of three-dimensionality in biology and provide a platform to increase the success rate in translating new degenerative or regenerative solutions (e.g., diagnostics, treatment, follow up) into real clinical innovative approaches to the benefit of patients. Original interdisciplinary research, pre-clinical methods validation and clinical investigations should be all considered as part of the shared open access knowledge which we are aiming to achieve with this Research Topic.
The overall scope of this Research Topic is to create a transparent forum of open access materials focused on the state of the art on 3D biology to date.
We encourage submissions addressing themes such as:
• Novel in vitro 3D models and organ-/lab-on-a-chip
• New methods/methodologies with application in 3D biology
• Drug testing using complex 3D in vitro cultures and/or in silico models
• Regulatory Science focused on 3D model validation
• Case studies focused on translational aspects for drug development
• Case studies focused on read-across methodologies
• Novel protocols and techniques for imaging and screening
• Screening of new materials for biomedical applications
• Regenerative and degenerative applications
• Predictive modelling for safety and personalized medicine
• Interdisciplinary original research in 3D biology
Original topical mini-review articles or perspectives focused on the current state of knowledge regarding the above mentioned themes are also welcome.
-----------------------------------------------------------------
Dr. Davide Staedler is CEO of TIBIO Sagl, a consulting company, and chief scientific officer of Scitec Research S.A., a private analytical laboratory. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
